Key result
Argatroban fails to improve neurological deficits over control in acute ischemic stroke.
Why the study?
Argatroban is a direct thrombin inhibitor used to treat acute ischemic stroke, but no systematic analysis had assessed its efficacy and safety in this setting.
Meta-Analysis (n=354)
Randomized controlled studies included
Yes
Relative Risk: 1.24 (95% CI 0.74–2.1)
p-value: p=0.42
Argatroban confers no neurological benefit in acute ischemic stroke; confirms inefficacy across trials and supports avoiding routine use.
BACKGROUND: Argatroban is a novel direct thrombin inhibitor that has been used for treatment of acute ischemic stroke (AIS). To our knowledge, no systematic analysis has assessed the efficacy and safety of argatroban for treatment of AIS. AIM: To evaluate the efficacy and safety of argatroban for treatment of AIS. METHODS: Cochrane Library, Medline, PubMed, and Web of Science were searched to retrieve all studies associated with argatroban and AIS. Effective rate, adverse events rate, and 95% confidence intervals were calculated and pooled using meta-analysis methodology. CONCLUSION: Patients with AIS might not benefit from argatroban and combination therapy with argatroban does not increase bleeding tendency.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2022) conducted a meta-analysis in Acute ischemic stroke (n=354). Argatroban vs. Control was evaluated on Effective rate of neurological deficit improvement (RR 1.24, 95% CI 0.74–2.10, p=0.42). Argatroban did not significantly improve neurological deficits compared with control in patients with acute ischemic stroke (RR 1.24, 95% CI 0.74–2.10; P = 0.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: